Breaking News

Natera continues patent battle with CareDx

Not rendering correctly? View this email as a web page here.

StartUPDATES: New developments from healthcare startups

By Stephanie Baum Friday, May 20, 2022 7:30 AM

Check out new developments from Carrum Health, ThoroughCare, Inceptor Bio and Gener8or accelerator.

Read more »

Exceptionalism—A core problem in healthcare leadership

By Joe Mandato and Ryan Van Wert MD Thursday, May 19, 2022 8:20 PM

We believe that healthcare leadership's ingrained culture of exceptionalism drives today's profound problem whereby patient satisfaction is low, inefficiency is high, and patient outcomes are poor.

Read more »

FDA sounds caution on Foghorn cancer drug with a partial hold after patient death

By Frank Vinluan Thursday, May 19, 2022 7:28 PM

The lead cancer drug candidate of Foghorn Therapeutics is now under a partial clinical hold following a patient death. According to the biotech, the patient may have experienced a side effect that is a known complication of leukemia drugs.

Read more »

How legal analytics will transform the pharmaceutical industry

By Aria Nejad Thursday, May 19, 2022 4:06 PM

Pharma companies already rely heavily on data and predictive analytics to assess new drugs. In the same way, analytics can be used to enhance legal advice and improve litigation strategies.

Read more »

House Energy and Commerce Committee passes bill outlining FDA procedures to withdraw a drug

By Amanda James Thursday, May 19, 2022 3:07 PM

To withdraw a drug from the market, the FDA will have to provide the drug sponsor with notice and an explanation as well as the opportunity to meet with the FDA, addressing increased scrutiny on the FDA's accelerated approvals program.

Read more »

Deciphex scores $11.5M in bid to address pathologist shortage

By Michael Schroeder Thursday, May 19, 2022 2:25 PM

The Dublin-based pathology software and services provider will use the funds to support global growth and launch an on-demand, online pathology service in the U.S.

Read more »

Enanta RSV drug fails a Phase 2 test, but studies continue in higher-risk patients

By Frank Vinluan Thursday, May 19, 2022 1:58 PM

An antiviral that Enanta Pharmaceuticals is developing for respiratory syncytial virus infection failed to beat a placebo in its first Phase 2 test. But the biotech notes that these study participants weren't very sick and may have recovered on their own, so it's now pinning its hopes on ongoing studies in higher-risk groups, such as transplant patients.

Read more »

Now is the time for health tech to capitalize on legislation moves

By Christie Callahan Thursday, May 19, 2022 10:28 AM

The onus is on providers, payers and their technology partners to use the new laws and market dynamics as a catalyst to fully achieve digital transformation in healthcare and improve the patient experience.

Read more »

   

No comments